Navigation Links
Nile Therapeutics, Inc. Completes $3.4 Million Private Placement
Date:7/16/2009

f unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rationally designed natriuretic peptide. More information on Nile can be found at http://www.nilethera.com.

Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding the sufficiency of Nile's available capital, timing, progress and anticipated results of the clinical development, regulatory processes, clinical trial timelines, anticipated benefits of CD-NP, Nile's strategy, future operations, outlook, milestones, the timing and success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. Nile may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on Nile's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Nile makes. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that Nile makes include Nile's need to raise additional capital to fund its product development programs to completion, Nile's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are descr
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
2. Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement
3. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
4. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
5. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
6. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
7. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
8. Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7
9. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
10. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
11. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Best Sanitizers, Inc., the first company ... sanitizer, asks food processors and food handling professionals to ... they’re currently using to Best Sanitizers’ Alpet® E3 ... to fighting cross-contamination and the spread of pathogens in ... are key criteria that make a hand sanitizer most ...
(Date:8/28/2014)... in spintronics, an electronic which is not only ... on their spin and the spin-related magnetism. Spin-charge ... signals and vice versa. Recently, the research group ... Physics at Johannes Gutenberg University Mainz in collaboration ... has for the first time realised a new, ...
(Date:8/28/2014)... executives from clinical trial marketing firm BBK Worldwide will lead ... Clinical Trials 2014 , to be held at the Hyatt ... Patient recruitment experts Bonnie A. Brescia , Matthew ... on the benefits of employing an effective patient engagement strategy, ... mobile apps – can be used to drive study participation ...
(Date:8/28/2014)... Aug. 28, 2014  Armetheon, Inc. ( www.armetheon.com ... mid- to late-stage cardiovascular drug candidates, today announced ... first round of financing. The Series A round ... Bioventures with participation from investors that included Atheneos ... Dr. Larry Hsu , the founder of ...
Breaking Biology Technology:Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3A new, tunable device for spintronics 2A new, tunable device for spintronics 3BBK Worldwide Leads Sessions at Key September Events 2Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3
... Top 25 Global Pharmaceutical Companies Select Drug ... Visualization, MOUNTAIN VIEW, Calif., April 2, 2008 ... provider of software,strategic consulting, and regulatory services for ... 25 global pharmaceutical,companies have become customers for its ...
... 1, 2008 MiMedx Group, Inc.,(OTC Bulletin Board: ... AYXC), today reported that the contemplated reverse stock ... related name change, to,MiMedx Group, Inc., was approved ... a result of the reverse split and redomestication, ...
... Installation and Major Data Migration in ... United States and Abroad, CHICAGO, April 1, ... signed an agreement with the Cleveland,Clinic, a not-for-profit ... deploy the syngo(R) Dynamics cardiology image,management and reporting ...
Cached Biology Technology:Pharsight Signs Two New DMX(R) License Customers 2Pharsight Signs Two New DMX(R) License Customers 3MiMedx Group Announces Post-split Name Change 2MiMedx Group Announces Post-split Name Change 3Siemens Signs Multi-Year Agreement With Cleveland Clinic to Deploy Enterprise-Wide Cardiology PACS 2
(Date:8/31/2014)... have discovered that ,good, cholesterol is turned ,bad, by ... MG, was found to damage ,good, HDL cholesterol, which ... , Low levels of HDL, High Density Lipoprotein, ... of MG being common in the elderly and those ... funding from the British Heart Foundation (BHF) and published ...
(Date:8/31/2014)... of satellite data from the last 19 years reveals that ... the coast of Antarctica to rise by 2cm more than ... of Southampton detected the rapid rise in sea-level by studying ... million square kilometres. , The melting of the ... has contributed an excess of around 350 gigatonnes of freshwater ...
(Date:8/29/2014)... SAN ANTONIO (Aug. 29, 2014) Scientists at the ... the School of Medicine at the UT Health Science ... longevity in the tissues of the longest-lived rodent, the ... factor in the cells of naked mole rats protects ... disposer for damaged and obsolete proteins. , The factor ...
Breaking Biology News(10 mins):Sugar substance 'kills' good HDL cholesterol, new research finds 2Factor in naked mole rat's cells enhances protein integrity 2
... lining , The intestines have to work properly if we ... must be secreted, the food broken down into smaller components ... muscles and organs. The lining of the gut is coated ... hormones while keeping dangerous bacteria and toxins at bay. Close ...
... August 30, 2010 The Metcalf Institute ... of Rhode Island Graduate School of Oceanography has ... RAPID Response grant through the Foundation,s office of ... Improving Communication of Oil Spill Research, will support ...
... 30th, 2010 Undergrads often take communication courses unrelated ... Department of Horticulture teamed up with the Library and ... students to research and understand literature searchers and incorporate ... Jeanine E. Aune, and Gail R. Nonnecke, Iowa State ...
Cached Biology News:Researchers to activate anti-cancer gene 2Metcalf Institute wins NSF grant to help journalism and communication of oil spill research 2Teaching communication and information literacy skills 2
Rabbit polyclonal to Somatostatin 28 ( Abpromise for all tested applications). entrezGeneID: 6750 SwissProtID: P61278...
... Features Convenient platform for tube ... - 96 x 0.2ml V-bottom tubes ... Thermo-Tube Plates - Thermo-Fast® 96 Non-Skirted ... - 48 x 0.5ml Thermo-Tubes Multiple ...
... Pro upgrade for Shimadzu Phoretix 2D, Expression ... statistical tools for comparative gel analysis studies ... Data base add on component ... version 9i release 2 client software). ...
... systems provide linking and labelling reagents ... specific primary antibodies for visualising cellular ... accomplished using an ultra-sensitive indirect labelling ... technology. Secondary antibodies are polymerised directly ...
Biology Products: